TY - JOUR
T1 - Dipeptidyl peptidase-4 inhibitors and joint pain
T2 - A retrospective cohort study of older veterans with type 2 diabetes mellitus
AU - Rai, Pragya
AU - Dwibedi, Nilanjana
AU - Rowneki, Mazhgan
AU - Helmer, Drew A.
AU - Sambamoorthi, Usha
N1 - Funding Information:
Source of Funding This work was supported by the Veterans Health Administration (VHA) Health Services Research & Development (grant number IIR 12-401). The content is solely the responsibility of the authors and does not necessarily represent the official views of the VHA, West Virginia University, or other affiliated organizations. Support for the Department of Veterans Affairs (VA)/Centers for Medicare & Medicaid Services data is provided by the VA, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, and VA Information Resource Center (project numbers SDR 02-237 and 98-004).
Funding Information:
This work was supported by the Veterans Health Administration (VHA) Health Services Research & Development (grant number IIR 12-401). The content is solely the responsibility of the authors and does not necessarily represent the official views of the VHA, West Virginia University, or other affiliated organizations. Support for the Department of Veterans Affairs (VA)/Centers for Medicare & Medicaid Services data is provided by the VA, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, and VA Information Resource Center (project numbers SDR 02-237 and 98-004).
Publisher Copyright:
© 2019 by Engage Healthcare Communications, LLC.
PY - 2019/9
Y1 - 2019/9
N2 - BACKGROUND: In recent years, dipeptidyl peptidase (DPP)-4 inhibitors have been added to the diabetes treatment algorithm. Few published studies have shown that the use of DPP-4 inhibitors is associated with joint pain. To our knowledge, no population-based studies in the United States have studied this association. OBJECTIVE: To evaluate the association between a new prescription of DPP-4 inhibitors and joint pain within 1 year among older veterans with diabetes. METHODS: This was a retrospective cohort study of older veterans (aged ≥66 years) who were dually enrolled in Medicare and the Veterans Health Administration (VHA; N = 134,488). Data were derived from linked Medicare claims and VHA electronic health records from 2008 to 2010. Diabetes during the baseline and joint pain during the follow-up period were identified with International Classification of Diseases, Ninth Revision codes. Filled prescriptions for DPP-4 inhibitors during the baseline period were identified from Medicare Part D and VHA pharmacy records. The adjusted associations between DPP-4 inhibitors and joint pain were examined with logistic regressions. RESULTS: Approximately 8.4% of the 134,488 study patients received at least 1 prescription for DPP-4 inhibitors and 11.7% were diagnosed with joint pain during the follow-up period. An unadjusted analysis showed significant differences in joint pain by DPP-4 inhibitor status (12.9% among users vs 11.6% among nonusers; P <.0001). In a fully adjusted model, having a DPP-4 inhibitor prescription had higher odds of joint pain (adjusted odds ratio, 1.17; 95% confidence interval, 1.10-1.24) compared with no prescription for a DPP-4 inhibitor. CONCLUSION: In a cohort of older veterans who did not have documented joint pain at baseline, a prescription for DPP-4 inhibitors was significantly associated with a newly documented joint pain.
AB - BACKGROUND: In recent years, dipeptidyl peptidase (DPP)-4 inhibitors have been added to the diabetes treatment algorithm. Few published studies have shown that the use of DPP-4 inhibitors is associated with joint pain. To our knowledge, no population-based studies in the United States have studied this association. OBJECTIVE: To evaluate the association between a new prescription of DPP-4 inhibitors and joint pain within 1 year among older veterans with diabetes. METHODS: This was a retrospective cohort study of older veterans (aged ≥66 years) who were dually enrolled in Medicare and the Veterans Health Administration (VHA; N = 134,488). Data were derived from linked Medicare claims and VHA electronic health records from 2008 to 2010. Diabetes during the baseline and joint pain during the follow-up period were identified with International Classification of Diseases, Ninth Revision codes. Filled prescriptions for DPP-4 inhibitors during the baseline period were identified from Medicare Part D and VHA pharmacy records. The adjusted associations between DPP-4 inhibitors and joint pain were examined with logistic regressions. RESULTS: Approximately 8.4% of the 134,488 study patients received at least 1 prescription for DPP-4 inhibitors and 11.7% were diagnosed with joint pain during the follow-up period. An unadjusted analysis showed significant differences in joint pain by DPP-4 inhibitor status (12.9% among users vs 11.6% among nonusers; P <.0001). In a fully adjusted model, having a DPP-4 inhibitor prescription had higher odds of joint pain (adjusted odds ratio, 1.17; 95% confidence interval, 1.10-1.24) compared with no prescription for a DPP-4 inhibitor. CONCLUSION: In a cohort of older veterans who did not have documented joint pain at baseline, a prescription for DPP-4 inhibitors was significantly associated with a newly documented joint pain.
KW - Dipeptidyl peptidase-4 inhibitors
KW - Hemoglobin A
KW - Joint pain
KW - Older veterans
KW - Type 2 diabetes mellitus
KW - Veterans Health Administration
UR - http://www.scopus.com/inward/record.url?scp=85074689076&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85074689076
SN - 1942-2962
VL - 12
SP - 223
EP - 231
JO - American Health and Drug Benefits
JF - American Health and Drug Benefits
IS - 5
ER -